Replication of HIV-1 deleted Nef mutants in chronically immune activated human T cells.
Lymphocytes (PBMC) obtained from blood of HIV-sera negative Ethiopian immigrants (ETH) were highly susceptible to HIV-1 infection in vitro with no need for stimulation by mitogens. As the HIV nef gene product has been shown to enhance viral replication in stimulated primary lymphocytes, we investigated in this work the role of Nef in viral replication in the ETH cells. Lymphocytes obtained from ETH individuals supported high replication of wild-type HIV-1 and low but significant replication level of the two deleted Nef mutants (encode truncated Nef proteins consisting only of either the first 35 or the first 86 amino acids of Nef). In contrast, no replication was observed in nonactivated cells obtained from non-ETH individuals. After activation of the PBMC from ETH individuals with PHA, replication of both wild-type strains and the two deleted Nef mutant viruses further increased. The CD4(+) T cells of ETH individuals exhibited elevated levels of the surface activation markers CD45RO and HLA-DR, compared with T cells derived from non-ETH group. Likewise, expression of the chemokine receptors CCR5 and CXCR4 on these cells was higher in the ETH group than in the non-ETH group. Replication of HIV-1 wild-type and the isogenic-deleted Nef mutants was significantly correlated with the proportion of ETH cells expressing CD45RO and the chemokine receptors. This study suggests that HIV-1 may respond differently to several activation states characteristic of T cells. One activation state, defined by chronically activated lymphocytes from ETH individuals, is permissive to the wild-type HIV-1 and, to a lesser degree, to the Nef mutants. Further activation of these cells by exogenous stimuli enhances replication of the virus. Our results support the notion that Nef enhances the basal level of T cell activation and consequently, viral replication.
Shapira-Nahor
Orit
O
Department of Virology, Hebrew University-Hadassah Medical School, Hadassah Hospital, Jerusalem, 91120, Israel. Orit.Nahor@huji.ac.il
Maayan
Shlomo
S
Peden
Keith W C
KW
Rabinowitz
Ruth
R
Schlesinger
Michael
M
Alian
Akram
A
Panet
Amos
A
D002478:Cells, Cultured; D005434:Flow Cytometry; D017353:Gene Deletion; D015693:Gene Products, nef / Q000235:genetics*; D015658:HIV Infections / Q000097:blood / Q000276:immunology* / Q000821:virology; D015497:HIV-1 / Q000235:genetics / Q000502:physiology*; D006684:HLA-DR Antigens / Q000032:analysis / Q000096:biosynthesis; D006801:Humans; D017493:Leukocyte Common Antigens / Q000032:analysis / Q000096:biosynthesis; D007963:Leukocytes, Mononuclear / Q000276:immunology; D019713:Receptors, CCR5 / Q000096:biosynthesis; D019718:Receptors, CXCR4 / Q000032:analysis / Q000096:biosynthesis; D013601:T-Lymphocytes / Q000276:immunology* / Q000821:virology; D014779:Virus Replication; D054311:nef Gene Products, Human Immunodeficiency Virus
D015693:Gene Products, nef; D006684:HLA-DR Antigens; D019713:Receptors, CCR5; D019718:Receptors, CXCR4; D054311:nef Gene Products, Human Immunodeficiency Virus; D017493:Leukocyte Common Antigens